drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Genetically engineered autologous T lymphocytes expressing a CD19-specific chimeric antigen receptor that activates T-cell cytotoxicity against CD19+ B-ALL cells, inducing B-cell aplasia and MRD eradication.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express a CD19-specific chimeric antigen receptor (scFv fused to costimulatory domain(s) and CD3z), enabling MHC-independent recognition of CD19 on B cells and B-ALL blasts; CAR signaling triggers T-cell activation, proliferation, cytokine release, and cytotoxic killing, leading to depletion of CD19+ cells, B-cell aplasia, and eradication of residual disease.
drug_name
Autologous CD19 CAR T cells (e.g., inaticabtagene autoleucel)
nct_id_drug_ref
NCT06608342